Recombinant Pan troglodytes D (2) dopamine receptor

What is the molecular structure of Pan troglodytes DRD2 and how does it compare to human DRD2?

The Pan troglodytes D (2) dopamine receptor (DRD2) is a G-protein-coupled receptor belonging to the D2-like family of dopamine receptors. Like human DRD2, it exhibits the archetypal topology consisting of seven transmembrane domains characteristic of G-protein coupled receptors. The receptor functions by inhibiting adenylyl cyclase activity through coupling with inhibitory G-proteins (Gi/o), thereby reducing intracellular cAMP levels .

Pan troglodytes DRD2 shows high sequence homology to human DRD2, reflecting their close evolutionary relationship. The receptor's structure includes:

• N-terminal extracellular domain

• Seven transmembrane α-helical domains

• Three extracellular loops

• Three intracellular loops (with the third intracellular loop being particularly important for G-protein coupling)

• C-terminal intracellular domain with palmitoylation sites

The receptor undergoes post-translational palmitoylation, which is required for proper localization to the plasma membrane and stability. This modification is carried out by palmitoylation enzymes including ZDHHC4, ZDHHC3, and ZDHHC8 .

What are the optimal expression systems for producing recombinant Pan troglodytes DRD2, and what are their comparative advantages?

Multiple expression systems are available for recombinant Pan troglodytes DRD2 production, each offering distinct advantages:

Commercial sources offer Pan troglodytes DRD2 expressed in these systems with purities of ≥85% as determined by SDS-PAGE . For functional studies, CHO-K1 cells co-expressing DRD2 with Gα15 have been successfully used to develop stable cell lines for drug screening and functional assays .

What purification protocols yield the highest purity of recombinant Pan troglodytes DRD2?

The optimal purification protocol depends on the expression system and intended application. Based on available data, standard purification achieves ≥85% purity as determined by SDS-PAGE . The following approaches are recommended:

For His-tagged recombinant DRD2:

• Immobilized Metal Affinity Chromatography (IMAC) using Ni-NTA or Co-NTA resins for primary purification

• Size Exclusion Chromatography (SEC) as a secondary step to remove aggregates and impurities

• Optional ion exchange chromatography for highest purity needs

To optimize membrane protein purification:

• Use mild detergents (DDM, LMNG, or CHS) during solubilization

• Maintain temperature at 4°C throughout purification

• Include glycerol (10%) and reducing agents in buffers for stability

• Consider lipid nanodiscs for native-like environment

For antibody-based approaches, immunogen affinity chromatography has been successfully applied for DRD2 antibodies . Quality control should include SDS-PAGE analysis, Western blotting with DRD2-specific antibodies, and functional validation through ligand binding assays.

What experimental methods are most effective for validating the functionality of recombinant Pan troglodytes DRD2?

Multiple complementary approaches should be employed to comprehensively validate DRD2 functionality:

• G-protein Activation Assays:

  • GTPγS binding assays to measure G-protein coupling efficiency

  • BRET-based G-protein dissociation assays for real-time activation monitoring

• Second Messenger Assays:

  • cAMP inhibition assays (DRD2 activation inhibits adenylyl cyclase)

  • Ca²⁺ mobilization assays in cells co-expressing DRD2 with Gα15

• Receptor Binding Assays:

  • Saturation binding with radioligands (e.g., [³H]spiperone)

  • Competition binding with unlabeled ligands to determine pharmacological profile

• Downstream Signaling Assays:

  • Western blot analysis for phosphorylation of downstream effectors

  • Monitoring activation of the Akt-GSK3 signaling pathway

Research has shown that DRD2 signals through two main pathways: G-protein-dependent signaling (inhibition of adenylyl cyclase) and G-protein-independent arrestin signaling . Both pathways should be evaluated when characterizing receptor function, as they may lead to different behavioral effects and could provide targets for developing more selective therapeutics with fewer side effects .

What techniques can distinguish between D2L and D2S splice variants in Pan troglodytes, and what are their functional differences?

DRD2 exists in two main splice isoforms with distinct functions: D2 long (D2L) and D2 short (D2S, lacking exon 6) . Distinguishing between these variants requires specific methodological approaches:

Molecular Biology Approaches:

• RT-PCR using primers flanking exon 6 (absent in D2S)

• qPCR with variant-specific primers

• RNA-Seq analysis with splice junction mapping

Protein Detection Methods:

• Western blotting (challenging due to small size difference)

• Mass spectrometry to detect peptides unique to D2L (from exon 6)

Functional Discrimination:

• D2L and D2S show differential G-protein coupling profiles

• D2S typically exhibits stronger presynaptic autoreceptor function

Functional Differences:

• D2L contains an additional 29 amino acids in the third intracellular loop

• D2L is predominantly expressed postsynaptically

• D2S is predominantly expressed presynaptically

• D2S shows higher affinity for dopamine and more efficient G-protein coupling

• D2L shows stronger β-arrestin recruitment

Research has shown that intronic single-nucleotide polymorphisms (SNPs rs2283265 and rs1076560) alter D2S/D2L splicing, reducing formation of D2S relative to D2L. These polymorphisms are significantly overrepresented in cocaine abusers compared to controls in Caucasian populations , suggesting functional significance of the D2S/D2L ratio.

How do the pharmacological properties of Pan troglodytes DRD2 compare to other species' DRD2 receptors?

The pharmacological properties of DRD2 show evolutionary conservation with some species-specific variations:

Pan troglodytes DRD2 represents the closest pharmacological match to human DRD2, making it valuable for translational studies. When characterizing the pharmacology of Pan troglodytes DRD2:

• Compare binding affinities of standard dopaminergic ligands

• Assess G-protein coupling efficiency

• Evaluate arrestin recruitment capabilities

• Determine potency/efficacy ratios for both signaling pathways

For dopamine receptor antagonists, D2 receptor occupancy has been linked to cognitive function in schizophrenia research, with specific occupancy thresholds associated with therapeutic effects versus side effects . Similar pharmacological principles likely apply to Pan troglodytes DRD2 given the high sequence conservation.

How can recombinant Pan troglodytes DRD2 be utilized in neuroinflammation research?

Recent research has revealed that DRD2 plays important roles in neuroinflammatory processes, opening new research directions:

Experimental approaches for studying DRD2 in neuroinflammation:

• In vitro models:

  • Microglial cultures expressing DRD2

  • Astrocyte-neuron co-cultures

  • Brain slice preparations

• In vivo models:

  • Intracerebral hemorrhage (ICH) models

  • Inflammatory challenge models (LPS, TNF-α)

  • Neurodegeneration models

Key experimental findings:

• DRD2 and its downstream protein CRYAB are upregulated in the injured hemisphere after ICH

• Exogenous administration of DRD2 agonists (quinpirole and ropinirole) demonstrates neuroprotective effects

• Activation of DRD2 suppresses neuroinflammation through specific signaling pathways

Experimental design considerations:

• Use specific DRD2 agonists like quinpirole (1-5 mg/kg) or ropinirole (5 mg/kg)

• Consider both intraperitoneal and intranasal delivery methods

• Validate with behavioral tests (modified Garcia test, forelimb placement)

• Assess brain edema and inflammatory marker expression

• Utilize DRD2 siRNA and CRYAB siRNA for mechanistic validation

These approaches allow investigation of Pan troglodytes DRD2's role in neuroinflammatory processes and development of potential therapeutic strategies for neuroinflammatory conditions.

What are the known functional polymorphisms affecting Pan troglodytes DRD2, and how do they compare to human polymorphisms?

While extensive data on Pan troglodytes DRD2 polymorphisms is limited, we can draw insights from human studies that may guide comparative research:

Human DRD2 Polymorphisms with Functional Significance:

• Intronic Splice-Affecting Polymorphisms:

  • rs2283265 (intron 5) and rs1076560 (intron 6) alter D2S/D2L splicing

  • These SNPs reduce formation of D2S relative to D2L

  • Associated with cocaine abuse in Caucasian populations (rs2283265: 25% in abusers vs 9% in controls)

  • Allele frequencies vary by population (18% in Caucasians vs 7% in African Americans)

• Promoter Polymorphisms:

  • Affect DRD2 expression levels

  • May influence response to dopaminergic drugs

• Coding Region Polymorphisms:

  • Alter receptor function or stability

  • Some variants associated with psychiatric disorders

Research approaches for Pan troglodytes DRD2 polymorphism studies:

• Comparative genomic analysis between human and Pan troglodytes DRD2

• Screening for orthologous polymorphisms in chimpanzee populations

• Functional characterization of identified variants using recombinant expression

• Differential allelic expression studies to identify cis-acting regulatory elements

Current research indicates that cis-acting loci affect DRD2 expression, as evidenced by differential expression of alleles in brain tissue . Similar regulatory mechanisms likely exist in Pan troglodytes, though direct experimental confirmation is needed.

What are the primary signal transduction pathways activated by Pan troglodytes DRD2, and how can they be experimentally measured?

DRD2 activates multiple signal transduction pathways that can be experimentally characterized:

• G-protein dependent pathways:

  • Inhibition of adenylyl cyclase via Gαi/o

  • Activation of K⁺ channels via Gβγ

  • Inhibition of Ca²⁺ channels via Gβγ

  • Activation of phospholipase C via Gβγ

• G-protein independent pathways:

  • β-arrestin recruitment

  • Formation of signaling complex with Akt, PP2A, and GSK3β

  • Regulation of MAPK/ERK pathway

Experimental methods to measure these pathways:

Research has shown that DRD2 receptors send signals through these two main pathways with different behavioral effects, suggesting the possibility of developing more targeted therapeutics with fewer side effects by selectively activating specific pathways .

In recombinant systems, Ca²⁺ responses can be measured when DRD2 is co-expressed with promiscuous G proteins like Gα15, allowing for real-time monitoring of receptor activation .

What structural biology techniques are most effective for studying Pan troglodytes DRD2, and what insights can they provide?

Advanced structural biology techniques offer powerful approaches to study DRD2 structure-function relationships:

• X-ray Crystallography:

  • Requires large quantities of highly purified, stable protein

  • Often utilizes fusion partners (T4 lysozyme, BRIL) to stabilize the receptor

  • Has been successfully applied to other GPCRs including human dopamine receptors

  • Provides atomic-level resolution of receptor structure

• Cryo-Electron Microscopy (Cryo-EM):

  • Increasingly powerful for membrane protein structures

  • Can capture different conformational states

  • Requires less protein than crystallography

  • Can visualize receptor-G protein complexes

• Nuclear Magnetic Resonance (NMR):

  • Useful for studying receptor dynamics

  • Can investigate ligand binding in solution

  • Requires isotopically labeled protein

• Molecular Dynamics Simulations:

  • Computational approach to study receptor dynamics

  • Can model ligand binding and conformational changes

  • Requires experimental structures as starting points

• Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):

  • Probes protein dynamics and conformational changes

  • Can identify regions affected by ligand binding

  • Requires less protein than crystallography or NMR

Structural insights enable:

• Identification of ligand binding pockets

• Understanding of activation mechanisms

• Design of more selective drugs

• Exploration of species differences in drug responses

• Investigation of receptor oligomerization

When studying recombinant Pan troglodytes DRD2, researchers should consider the receptor's membership in the G-protein coupled receptor 1 family and its characteristic seven transmembrane domain topology that is evolutionarily conserved across species .

How can recombinant Pan troglodytes DRD2 research contribute to understanding human dopamine-related disorders?

Recombinant Pan troglodytes DRD2 research offers valuable insights into human dopamine-related disorders due to high evolutionary conservation:

• Schizophrenia Research:

  • DRD2 is a primary target for antipsychotic medications

  • D2 receptor occupancy correlates with cognitive function in schizophrenia

  • Comparative studies can identify conserved mechanisms of antipsychotic action

• Parkinson's Disease Applications:

  • DRD2 agonists are key treatments for Parkinson's disease

  • Recombinant receptor studies can evaluate drug efficacy and mechanisms

  • Comparative analysis may reveal species-specific responses to dopaminergic agents

• Addiction Studies:

  • DRD2 polymorphisms affect vulnerability to substance abuse

  • Intronic polymorphisms affecting splicing are overrepresented in cocaine abusers

  • Recombinant systems allow investigation of how genetic variants alter receptor function

• Neuroinflammatory Conditions:

  • DRD2 activation suppresses neuroinflammation after intracerebral hemorrhage

  • DRD2 agonists (quinpirole, ropinirole) show therapeutic potential in brain injury

  • Understanding DRD2's role may lead to novel anti-inflammatory approaches

• Translational Research:

  • Development of biased ligands that selectively activate beneficial signaling pathways

  • Testing of novel therapeutic compounds with improved specificity

  • Investigation of side effect mechanisms (weight gain, movement disorders)

The close evolutionary relationship between Pan troglodytes and human DRD2 makes this research particularly valuable for translational applications, while allowing for controlled experimental conditions that may not be possible in human studies.

What determines G-protein coupling specificity of Pan troglodytes DRD2, and how can this be experimentally manipulated?

G-protein coupling specificity of DRD2 involves complex structural determinants that can be experimentally investigated:

Key Determinants of G-protein Coupling:

• Intracellular Loops:

  • The third intracellular loop (IL3) plays a critical role in G-protein coupling specificity

  • The D2L variant contains an additional 29 amino acids in IL3 compared to D2S

  • IL3 contains sites for interactions with G-proteins and other signaling proteins

• C-terminal Tail:

  • Contains phosphorylation sites that regulate desensitization and internalization

  • Mutations in this region can alter G-protein coupling efficiency

• Transmembrane Domains:

  • TM5, TM6, and TM7 undergo conformational changes upon activation

  • These changes expose binding sites for G-protein interaction

Experimental Manipulation Approaches:

• Site-Directed Mutagenesis:

  • Targeted mutations in IL3 or C-terminal domains

  • Creation of chimeric receptors with segments from other GPCRs

  • Mutation of key residues in the "DRY" motif at the cytoplasmic end of TM3

• Expression System Modification:

  • Co-expression with different G-protein subunits

  • Expression in cell lines lacking specific G-proteins

  • Use of pertussis toxin to inactivate Gi/o proteins

• Pharmacological Manipulation:

  • Use of biased ligands that preferentially activate G-protein or arrestin pathways

  • Application of G-protein or arrestin pathway inhibitors

• Measuring Coupling Efficiency:

  • GTPγS binding assays

  • BRET/FRET-based G-protein activation sensors

  • Measurement of downstream effectors (cAMP, Ca²⁺, ERK phosphorylation)

Research has shown that in the distal Lys369LysAlaThrGln373 region, mutations can significantly affect G-protein activation . Additionally, studies have demonstrated that DRD2 can signal via G-protein-independent arrestin pathways, offering opportunities for pathway-selective drug development .

Understanding G-protein coupling specificity is crucial for developing more selective therapeutic agents with improved efficacy and reduced side effects.

What are the optimal experimental designs for utilizing recombinant Pan troglodytes DRD2 in drug discovery applications?

Effective drug discovery applications using recombinant Pan troglodytes DRD2 require careful experimental design:

• Cell-Based Screening Systems:

  • Stable cell lines expressing DRD2 (CHO-K1/D2/Gα15 is well-validated)

  • Inducible expression systems to control receptor density

  • Reporter gene assays linked to specific signaling pathways

  • BRET/FRET-based assays for real-time monitoring

• Primary Screening Assays:

  • Calcium mobilization assays when DRD2 is co-expressed with Gα15

  • cAMP inhibition assays (measure inhibition of forskolin-stimulated cAMP)

  • β-arrestin recruitment assays

  • Radioligand binding displacement assays

• Secondary/Confirmatory Assays:

  • GTPγS binding to measure direct G-protein activation

  • ERK phosphorylation

  • Receptor internalization

  • Electrophysiological measurements in native neurons

• Counter-Screening:

  • Testing against related dopamine receptors (D1, D3, D4, D5)

  • Screening against other monoamine receptors (serotonin, adrenergic)

  • Off-target effect evaluation using receptor panels

• Advanced Pharmacological Characterization:

  • Bias factor calculation (G-protein vs. arrestin pathway activation)

  • Residence time measurements (receptor-ligand complex stability)

  • Allosteric modulator identification

Practical Implementation Guidelines:

• Maintain stable cell lines within 16 passages for consistent results

• Include positive controls (quinpirole, bromocriptine) and reference antagonists (haloperidol, raclopride)

• Use multiple concentrations to generate full dose-response curves

• Normalize responses to a reference compound

• Include appropriate vehicle controls

This approach allows for comprehensive evaluation of compound activity at Pan troglodytes DRD2, identifying compounds with desired efficacy, selectivity, and signaling profiles. The high similarity between Pan troglodytes and human DRD2 makes this a valuable translational research tool.

What methodologies best characterize alternative splicing of Pan troglodytes DRD2, and what functional impact does this have?

Alternative splicing of DRD2 produces functionally distinct receptor variants that require specialized methodologies for characterization:

Analysis Techniques:

• Molecular Detection Methods:

  • RT-PCR using primers spanning exon 6 (present in D2L, absent in D2S)

  • Quantitative real-time PCR with splice variant-specific primers

  • Droplet digital PCR for absolute quantification of splice variant ratio

  • RNA-Seq with specialized splice junction analysis

• Protein Level Detection:

  • Western blotting (challenging due to small size difference)

  • Mass spectrometry to identify isoform-specific peptides

  • Immunoprecipitation with variant-specific antibodies

• Functional Characterization:

  • Electrophysiological recordings to detect presynaptic vs. postsynaptic effects

  • G-protein coupling efficiency measurements

  • Arrestin recruitment assays

  • Receptor trafficking studies

Impact of Alternative Splicing:

The D2L and D2S variants differ by 29 amino acids in the third intracellular loop, resulting in several functional differences:

Research has shown that intronic polymorphisms (rs2283265 and rs1076560) affect the splicing of human DRD2, reducing formation of D2S relative to D2L. These polymorphisms are significantly overrepresented in cocaine abusers compared to controls in Caucasian populations . Similar genetic regulation mechanisms may exist in Pan troglodytes, though specific investigation is needed.

The ratio of D2S/D2L can significantly impact dopaminergic signaling and responses to dopaminergic drugs, making alternative splicing a critical consideration in DRD2 research and drug development.

What quality control measures ensure the reliable production and characterization of recombinant Pan troglodytes DRD2?

Rigorous quality control is essential for reliable recombinant DRD2 research:

• Expression System Validation:

  • Verification of expression vector sequence

  • Confirmation of cell line authenticity

  • Mycoplasma testing of host cells

  • Passage number monitoring (stability typically maintained for 16 passages)

• Protein Production Quality Control:

  • SDS-PAGE analysis (target: ≥85% purity)

  • Western blot using validated DRD2 antibodies

  • Mass spectrometry to confirm identity and integrity

  • Glycosylation analysis for mammalian expression systems

• Structural Integrity Assessment:

  • Circular dichroism spectroscopy to confirm secondary structure

  • Fluorescence spectroscopy to assess tertiary folding

  • Thermal stability assays

  • Limited proteolysis to verify correct folding

• Functional Validation:

  • Radioligand binding assays (saturation and competition)

  • G-protein activation assays (GTPγS binding)

  • Second messenger assays (cAMP inhibition)

  • Calcium mobilization when co-expressed with Gα15

• Storage and Stability:

  • Optimized freezing media (45% culture medium, 45% FBS, 10% DMSO)

  • Proper storage conditions (liquid nitrogen for long-term storage)

  • Stability testing over time and freeze-thaw cycles

  • Batch-to-batch consistency evaluation

• Documentation Requirements:

  • Comprehensive record-keeping of expression conditions

  • Detailed purification protocols

  • Quality control test results for each batch

  • Standard operating procedures (SOPs) for all processes

Implementation of these quality control measures ensures that research conducted with recombinant Pan troglodytes DRD2 is reliable and reproducible. Commercial providers typically perform these validations, with product specifications including host cell information, gene accession numbers, purification methods, and functional validation data .